Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Han, Sun-Hoa; 1 | Jung, Eun Suna; 1 | Sohn, Ji-Hoona | Hong, Hyun Jooa | Hong, Hyun Seoke | Kim, Jong Wonb | Na, Duk Lyulc | Kim, Manhod | Kim, Heee | Ha, Hee Jine | Kim, Young Hoe | Huh, Namjungf | Jung, Min Whanf | Mook-Jung, Inheea; *
Affiliations: [a] Department of Biochemistry and Biomedical Science, Seoul National University, College of Medicine, Seoul, Korea | [b] Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea | [c] Department of Neurology, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea | [d] Department of Neurology, Seoul National University, College of Medicine, Seoul, Korea | [e] Digital Biotech, Inc., Gyeongi, Korea | [f] Biomedical Science Institute, Ajou University, School of Medicine, Suwon, Korea
Correspondence: [*] Correspondence to: Inhee Mook-Jung, PhD, Department of Biochemistry and Biomedical Science, Seoul National University, College of Medicine, 28 Yungun-dong, Jongro-gu, Seoul 110-799, Korea. Tel.: +82 2 740 8245; Fax: +82 2 3672 7352; E-mail: inhee@snu.ac.kr.
Note: [1] Contributed equally to this report.
Abstract: Alzheimer's disease (AD) is the fastest growing neurodegenerative disease in the elderly population, and the search for therapeutic targets and diagnostic AD biomarkers is an exigent issue. Because amyloid-β (Aβ) aggregation constitutes the epicenter of AD pathology, Aβ-binding proteins that regulate Aβ aggregation, such as transthyretin (TTR), have attracted much attention. TTR binds to Aβ, prevents its aggregation, and consequently inhibits Aβ-induced cellular toxicity. Decreased TTR levels in cerebrospinal fluid (CSF) from AD patients suggest that TTR is a biomarker of AD. But, studies on TTR as a biomarker have focused on CSF; no study has evaluated peripheral levels of TTR in AD. Here, we examined the relationship between serum TTR levels and AD. We measured TTR levels in serum samples from 90 nondemented controls and 111 AD patients and observed significantly lower serum TTR levels in AD (p < 0.001). Notably, females in the control group had lower serum TTR levels compared with male in the control (p = 0.006), while no difference in gender was noted in the AD group. There were no age-related changes in serum TTR levels. Thus, this study demonstrates a clear negative correlation between serum TTR levels and AD, suggesting that TTR is not only involved in AD pathological process but also suggested as possible peripheral biomarker for AD diagnosis in serum level.
Keywords: Alzheimer's disease, amyloid-β aggregation, biomarker, serum, transthyretin
DOI: 10.3233/JAD-2011-102145
Journal: Journal of Alzheimer's Disease, vol. 25, no. 1, pp. 77-84, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl